{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"description":"An adverse event (AE) is any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it was related to the medicinal product. A TEAE is defined as any AE that occurred after administration of the first dose of any study drug through 30 days after the last dose of any study drug.","groups":[{"description":"Ixazomib 4 mg, capsules, orally on Days 1, 8, and 15 plus lenalidomide 25 mg, capsule, orally, once daily on Days 1 through 21 and dexamethasone 40 mg, tablet, orally on Days 1, 8, 15, and 22 of a 28-day cycle up to 32 cycles.","id":"OG000","title":"Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set included all participants who received at least one dose of study drug during the treatment period.","reportingStatus":"POSTED","timeFrame":"Up to approximately 33 months","title":"Number of Participants With One or More Treatment-emergent Adverse Events (TEAEs)","type":"SECONDARY","unitOfMeasure":"Participants"}